Beta-blockers may be safely discontinued after heart attack recovery, NEJM study finds

The SMART-DECISION trial (n=2,540) found no difference in heart attack recurrence or mortality when stopping beta-blockers after >1 year: incidence 7.2% in the discontinuation group vs 9.0% in the continuation group. Published in the New England Journal of Medicine, the study supports stopping beta-blockers for stable post-MI patients without heart failure or left ventricular dysfunction and could reduce unnecessary long-term use, side effects, and related drug costs.

Analysis

Near-term commercial winners are firms that provide diagnostic/monitoring workflows needed to support individualized deprescribing: ambulatory ECG/AI-read services and remote patient monitoring vendors stand to capture higher per-patient revenue as clinicians shift from blanket pharmacotherapy to active surveillance. If even a fraction of long-term beta-blocker users are evaluated for step-down therapy, incremental monitoring revenue could rise 10–30% for category leaders over 12–36 months because each deprescribing episode typically requires serial ECGs, follow-up visits, and data interpretation.

The clearest losers are low-margin generic manufacturers and distributors whose beta-blocker volumes represent a non-trivial SKU base; a 5–15% secular reduction in chronic beta-blocker scripts across developed markets would meaningfully compress near-term revenue for companies with concentrated generics exposure. Downstream players — PBMs and retail pharmacies — will see modest script-volume declines offset by retained dispensing economics, so the net profit impact there will be much smaller than headline prescription counts imply.

Primary risks that could unwind these second-order effects are slow guideline adoption, differences in multi-ethnic real-world populations, and medico-legal caution among clinicians — any of which could push meaningful change beyond a 12–24 month window. Conversely, rapid payer-driven de-implementation programs or regulatory endorsement would compress that timeline to 3–12 months and amplify effects across manufacturers and device vendors.

The consensus underestimates implementation frictions: many patients have comorbid indications for beta-blockers and prescribers are conservative about deprescribing absent clear protocols, so the durable market impact on global beta-blocker revenue is likelier in the low-single-digit percentage range over the next 1–3 years. That makes high-conviction short positions on diversified big-cap pharma risky; targeted exposure to generics and a paired long in cardiac monitoring captures asymmetric upside if protocolized deprescribing scales.

Key Decisions for Investors

• Short TEVA (TEVA) or buy 6–12 month ATM/near-ATM puts (size 1–2% of portfolio). R/R: limited carry cost; downside scenario ~5–15% if guideline-driven volume loss accelerates. Risk: diversified portfolio of TEVA mutes impact—use 15% stop-loss or hedge with broad pharma index.
• Buy iRhythm (IRTC) 12-month calls or buy-and-hold shares (size 1–3%). Thesis: 12–36 month revenue tail from increased ambulatory monitoring per deprescribing episode; upside if reimbursement improves. Risk: reimbursement lag and competition—take profits at 30–50% or on adverse CMS guidance.
• Overweight UnitedHealth (UNH) (size 1–2%) for 6–12 months to capture modest pharmacy margin tailwind as PBMs/payers optimize chronic drug spend. R/R: 20–50 bps incremental margin could re-rate modestly; downside: broader healthcare risk cycles—use 10% stop-loss.
• Pair trade: short Viatris (VTRS) or other small-cap generics (size 1%) vs long IRTC (size 1%) over 6–24 months. This isolates exposure to loss of chronic beta-blocker volume while keeping upside to monitoring adoption. Risk controls: stop-loss at 15% on either leg or unwind after major guideline decision by ACC/AHA/EMA.